Resverlogix Plunges 93% After Drug Trial Fails

Resverlogix Corp. (RVX) sank the most on record after saying its drug to fight thickening of the arteries failed to meet its primary target in a phase 2 clinical trial.

Resverlogix, based in Calgary, plunged 93 percent to 23 cents at 4 p.m. in Toronto, the most since its initial public offering in 2001. The stock has now fallen 86 percent this year, giving it a market value of C$17.2 million ($16.4 million).

Test results from a 26-week Phase 2b clinical trial showed patients treated with the RVX-208 drug had a 0.4 percent reduction in plaque levels, short of the 0.6 percent target drop.

“We remain focused on analyzing the full data set over the coming weeks and months to determine whether continued development of RVX-208 in cardiovascular disease is warranted,” Donald McCaffrey, Resverlogix’s chief executive officer, said in a statement.

The drug is intended to work by boosting production of a particle required in a process called reverse cholesterol transport, in which plaque in the arteries is removed from the body using the liver.

To contact the reporter on this story: Eric Lam in Toronto at elam87@bloomberg.net

To contact the editor responsible for this story: Lynn Thomasson at lthomasson@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.